Genetic Rx panel on gene therapy to feature Renova Therapeutics CEO and Co-founder
December 1, 2016
San Diego, CA – Renova™ Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced that the company’s CEO and Co-founder, Jack W. Reich, Ph.D., will be speaking on a panel about gene therapy at Genetic Rx, a networking conference of the Boston Biotech Conferences series. The conference will be held at Harvard Medical School on December 8.
Dr. Reich to speak on gene therapy at Genetic Rx on Dec. 8, 2016
Genetic Rx is focused on the emergence of new genetic medicines and therapies, as well as the treatment of patients with rare and ultra-rare genetic diseases. Dr. Reich will be featured on a panel entitled “Gene Therapy: New Therapeutic Modalities” to provide his perspective on gene therapies focused on chronic cardiovascular and metabolic diseases.
A pioneer in gene therapy, Dr. Reich hopes to engage with like-minded industry leaders and provide valuable perspective on the possibilities of the field, beyond treating diseases that affect small subsets of the world population. “While much of gene therapy research to date has concentrated on rare diseases and cancers, our efforts are focused on chronic diseases affecting many millions of patients worldwide, like heart failure and type 2 diabetes,” he says.
“I look forward to discussing the Renova Therapeutics approach to gene therapy at Genetic Rx,” says Dr. Reich. “We envision a future in which we’re able to treat major conditions in this novel way, instead of relying primarily on small-molecule drugs.”
The panel will also comprise industry executives from Abeona Therapeutics, Allergan, Pfizer and Precision BioSciences. Genetic Rx is sponsored by Pfizer and the BioPharma Executive Council.
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company’s lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company’s product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.
About the Boston Biotech Conferences (BBC)
The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of bio-pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry’s challenges and opportunities. For more information or to register, visit http://www.bbbiotechconference.com.